

Synthesis of Some New Biologically Active Benzothiazole Derivatives Containing Benzimidazole and Imidazoline Moieties

Manish Chaudhary, Deepak Pareek, Pawan K. Pareek,[†] Ravi Kant,[‡] Krishan G Ojha,[†] and Arun Pareek^{*}

Analytical & Pharmaceutical Research Laboratory, Department of Chemistry, Government College Ajmer, 305001 India

^{*}E-mail: arunpareek7@gmail.com

[†]Department of Pure and Applied Chemistry, M. D. S. University, Ajmer 305009 India

[‡]Hygia Institutes of Pharmaceutical Education and Research, Lucknow, 226020 India

Received June 30, 2010, Accepted November 2, 2010

Synthesis of *N*-(1*H*-benzimidazol-2-yl)-6-substituted-1,3-benzothiazol-2-amines and 6-substituted-*N*-(4,5-dihydro-1*H*-imidazol-2-yl)-1,3-benzothiazol-2-amines by the reaction of substituted 2-aminobenzothiazoles with carbon disulphide and methyl iodide followed by the reaction with *o*-phenylene diamine/ethylene diamine are reported. All the synthesized compounds were characterized by elemental analysis, IR spectra and ¹H NMR spectral studies. The potent antibacterial and entomological (antifeedant, acaricidal, contact toxicity and stomach toxicity) activities of the synthesized compounds were investigated.

Key Words: Benzothiazole, Benzimidazole, Imidazoline, Antibacterial activity, Entomological activity

Introduction

Benzothiazole derivatives have been studied extensively and found to have diverse chemical reactivity and broad spectrum of biological activity such as antitumor agents,¹⁻³ antimicrobial,⁴⁻⁶ analgesics,⁷ anti-inflammatory,⁷⁻⁹ anti HIV,¹⁰ antileishmanial,¹¹ etc. Further a wide range of therapeutic activities of benzimidazole show that they are also anticancer,¹² antihypertension,¹³ antioxidant,¹⁴ antiviral,¹⁵ proton pump blocker,¹⁶ antinociceptive,¹⁷ anti-inflammatory,^{17,18} analgesic,¹⁸ antiparasites,¹⁹ human cytomegalovirus (HCMV) replication inhibitor,²⁰ fungicidal,²¹ antihistamines,^{22,23} etc. Similarly Imidazoline derivatives also possess an array of biological activities. They are useful as anticancer,^{24,25} anti-inflammatory,²⁵ Anthelmintic,²⁶ antimicrobial,²⁷ hypnotic agents,²⁸ antiviral,²⁹ anticoagulant,³⁰ etc. These reports prompted us for synthesis of some new benzothiazole derivatives containing benzimidazole and imidazoline moiety. Substituted 2-aminobenzothiazole (**1**) was prepared by

thiocyanogenation of substituted anilines by the method reported earlier.^{31,32} These were reacted with carbon disulphide and methyl iodide in presence of con. NaOH aqueous solution leading to the formation of dimethyl (substituted-1,3-benzothiazol-2-yl) dithioimidocarbonate derivative (**2**) which was treated with bisnucleophiles viz. *o*-phenylene diamine and ethylene diamine gave *N*-(1*H*-benzimidazol-2-yl)-6-substituted-1,3-benzothiazol-2-amine (**3**) and 6-substituted-*N*-(4,5-dihydro-1*H*-imidazol-2-yl)-1,3-benzothiazol-2-amine (**4**) (Scheme 1). The synthesized compounds were characterized by their elemental analysis, IR and ¹H NMR spectral studies. Antibacterial and entomological studies have been screened to observe their various biological activities.


Experimental

Reagent grade chemicals were used without further purification. Melting points were taken in open capillary tubes are uncorrected. The purity of the synthesized compounds was checked by Thin Layer Chromatographic studies. IR spectra were scanned on FT IR Perkins Elmer (Spectrum RX1) spectrophotometer (cm⁻¹) using a KBr disc. ¹H NMR spectra was recorded in tetramethylsilane (TMS) as the internal standard at 300 MHz on a Bruker DRTX-300 spectrophotometer.

General Procedure for the Synthesis of 4/6-Substituted Benzimidazole.

Synthesis of Substituted-2-aminobenzothiazole Derivatives (1): Substituted-2-aminobenzothiazoles (**1**) were prepared as reported earlier.^{31, 32}

Synthesis of Dimethyl(substituted-1,3-benzothiazol-2-yl)dithioimidocarbonate Derivatives (2): To a well stirred ice cold solution of (**1**) (0.025 mole) in dimethylformamide (10 mL), were added 10 M NaOH aqueous solution (4 mL), carbon disulphide (0.05 mole) and methyl iodide (0.025 mole) in sequence at an interval of 30 min. and stirring was continued for 3 hrs. The mixture was then poured in ice cold water and the



Scheme 1

Table 1. Physical and chemical data of synthesized compounds

Compound	R	R ¹	Mol. Formula	Mol. Weight	Melting point (°C)	Yield (%)
1A	H	Br	C ₇ H ₅ BrN ₂ S	229.097	190 - 194	70
1B	H	F	C ₇ H ₅ FN ₂ S	168.191	183 - 185	68
1C	CH ₃	H	C ₈ H ₈ N ₂ S	164.227	137 - 139	58
1D	H	OC ₂ H ₅	C ₉ H ₁₀ ON ₂ S	194.253	161 - 163	72
1E	H	CH ₃	C ₈ H ₈ N ₂ S	164.227	140 - 143	55
2A	H	Br	C ₁₀ H ₉ BrN ₂ S ₃	333.290	269 - 271	70
2B	H	F	C ₁₀ H ₉ FN ₂ S ₃	272.391	190 - 194	65
2C	CH ₃	H	C ₁₁ H ₁₂ N ₂ S ₃	268.427	104 - 106	58
2D	H	OC ₂ H ₅	C ₁₂ H ₁₄ ON ₂ S ₃	298.447	187 - 191	80
2E	H	CH ₃	C ₁₁ H ₁₂ N ₂ S ₃	268.427	109 - 112	59
3A	H	Br	C ₁₄ H ₉ BrN ₄ S	345.217	274 - 277	60
3B	H	F	C ₁₄ H ₉ FN ₄ S	284.311	259 - 262	52
3C	CH ₃	H	C ₁₅ H ₁₂ N ₄ S	280.347	256 - 260	48
3D	H	OC ₂ H ₅	C ₁₆ H ₁₄ ON ₄ S	310.373	269 - 272	68
3E	H	CH ₃	C ₁₅ H ₁₂ N ₄ S	280.347	262 - 265	50
4A	H	Br	C ₁₀ H ₉ BrN ₄ S	297.174	220 - 223	82
4B	H	F	C ₁₀ H ₉ FN ₄ S	236.268	224 - 227	75
4C	CH ₃	H	C ₁₁ H ₁₂ N ₄ S	232.304	259 - 262	58
4D	H	OC ₂ H ₅	C ₁₂ H ₁₄ ON ₄ S	262.330	204 - 206	65
4E	H	CH ₃	C ₁₁ H ₁₂ N ₄ S	232.304	236 - 240	65

resulting solid was washed with water and recrystallised from aq. ethanol. Physical and chemical data of synthesized compounds are given in Table 1.

Dimethyl (6-Bromo-1,3-benzothiazol-2-yl) Dithioimidocarbonate Derivatives (2A) – Yield 70%. Anal. Calcd for C₁₀H₉BrN₂S₃: C - 36.04%, N - 8.41%, H - 2.72%, Found C - 36.14%, N - 8.45%, H - 2.78%; IR (KBr) 3069, 1599, 1502, 1172, 1081, 809, 753 and 635 (benzothiazole with aromatic ring), 2880 (aliphatic CH), 1632 (C=N), 1263, 1310 (C-S), 561 (C-Br), ¹H NMR (300 MHz, DMSO-*d*₆): 2.65 (s, 6H, 2 × SCH₂); 6.98-7.38 (m, 3H, Ar-H).

Dimethyl (6-Fluoro-1,3-benzothiazol-2-yl) Dithioimidocarbonate Derivatives (2B) – Yield 65%. Anal. Calcd for C₁₀H₉FN₂S₃: C - 44.09%, N - 10.28%, H - 3.33%, Found C - 44.05%, N - 10.25%, H - 3.28%; IR (KBr) 3050, 1549, 1506, 1161, 1047, 837, 745 and 631 (benzothiazole with aromatic ring), 2905 (aliphatic CH), 1628 (C=N), 1309, 1244 (C-S), 1005 (C-F), ¹H NMR (300 MHz, DMSO-*d*₆): 2.68 (s, 6H, 2 × SCH₂); 7.08-7.29 (m, 3H, Ar-H).

Dimethyl (4-Methyl-1,3-benzothiazol-2-yl) Dithioimidocarbonate Derivatives (2C) – Yield 58%. Anal. Calcd for C₁₁H₁₂N₂S₃: C - 49.22%, N - 10.44%, H - 4.51%, Found C - 49.20%, N - 10.39%, H - 4.45%; IR (KBr) 3077, 1601, 1455, 1163, 1081, 840, 735 and 658 (benzothiazole with aromatic ring), 2895 (aliphatic CH), 1635 (C=N), 1312, 1260 (C-S), ¹H NMR (300 MHz, DMSO-*d*₆): 2.58 (s, 6H, 2 × SCH₂); 2.45 (s, 3H, Ar-CH₃), 7.12-7.53 (m, 3H, Ar-H).

Dimethyl (6-Ethoxy-1,3-benzothiazol-2-yl) Dithioimidocarbonate Derivatives (2D) – Yield 80%. Anal. Calcd for C₁₂H₁₄ON₂S₃: C - 48.29%, N - 9.39%, H - 4.73%, Found C - 48.35%, N - 9.45%, H - 4.79%; IR (KBr) 3095, 1605, 1482, 1178, 1020, 832, 735 and 675 (benzothiazole with aromatic ring), 2892 (aliphatic CH), 1632 (C=N), 1366, 1221 (C-S), 1260 (C-O-C), ¹H

NMR (300 MHz, DMSO-*d*₆): 1.52 (t, 3H, OCH₂CH₃); 2.52 (s, 6H, 2 × SCH₂); 4.02 (q, 2H, Ar OCH₂), 7.14-7.43 (m, 3H, Ar-H).

Dimethyl (6-Methyl-1,3-benzothiazol-2-yl) Dithioimidocarbonate Derivatives (2E) – Yield 58%. Anal. Calcd for C₁₁H₁₂N₂S₃: C - 49.22%, N - 10.44%, H - 4.51%, Found C - 49.19%, N - 10.40%, H - 4.58%; IR (KBr) 3086, 1605, 1464, 1160, 1085, 835, 732 and 665 (benzothiazole with aromatic ring), 2895 (aliphatic CH), 1635 (C=N), 1312, 1260 (C-S), ¹H NMR (300 MHz, DMSO-*d*₆): 2.62 (s, 6H, 2 × SCH₂); 2.41 (s, 3H, Ar-CH₃), 7.20-7.49 (m, 3H, Ar-H).

Synthesis of N-(1*H*-Benzimidazol-2-yl)-substituted-1,3-benzothiazol-2-amine Derivatives (3): To a solution of **2** (5.0 mmol) in DMF (20 mL) was added in solution of *o*-phenylene diamine (4.0 mmole) in DMF (15 mL) with stirring at room temp. The reaction mixture was reflux for 8 hrs. The mixture was poured on crushed ice. The resulting solid was dried and recrystallised from ethanol. Physical and chemical data of synthesized compounds are summarized in Table 1.

N-(1*H*-Benzimidazol-2-yl)-6-bromo-1,3-benzothiazol-2-amine (3A) – Yield 60%. Anal. Calcd for C₁₄H₉BrN₄S: C - 48.71%, N - 16.23%, H - 2.63%, Found C - 48.68, N - 16.20%, H - 2.61%; IR (KBr) 3072, 1540, 1470, 1150, 1051, 810, 743 and 640 (benzothiazole with aromatic ring), 3369 (N-H), 1635 (C=N), 1308 (C-S), 590 (C-Br), ¹H NMR (300 MHz, DMSO-*d*₆): 6.10 (s, 1H, acyclic NH); 7.10-7.43 (m, 7H, Ar-H); 8.04 (s, 1H, cyclic NH).

N-(1*H*-Benzimidazol-2-yl)-6-fluoro-1,3-benzothiazol-2-amine (3B) – Yield 52%. Anal. Calcd for C₁₄H₉FN₄S: C - 59.14%, N - 19.71%, H - 3.19%, Found C - 54.18, N - 19.75%, H - 3.21%; IR (KBr) 3068, 1568, 1478, 1108, 1068, 808, 740 and 658 (benzothiazole with aromatic ring), 3355 (N-H), 1638 (C=N), 1315 (C-S), 1008 (C-F), ¹H NMR (300 MHz, DMSO-*d*₆): 5.74 (s, 1H, acyclic NH); 6.91-7.33 (m, 7H, Ar-H); 8.07 (s, 1H, cyclic NH).

N-(1*H*-Benzimidazol-2-yl)-4-methyl-1,3-benzothiazol-2-amine (3C) – Yield 48%. Anal. Calcd for C₁₅H₁₂N₄S: C - 64.26%, N - 19.98%, H - 4.31%, Found C - 64.28, N - 19.97%, H - 4.35%; IR (KBr) 3087, 1603, 1462, 1156, 1073, 841, 728 and 683 (benzothiazole with aromatic ring), 3357 (N-H), 1644 (C=N), 2887 (CH), 1304 (C-S), ¹H NMR (300 MHz, DMSO-*d*₆): 2.50 (s, 3H, CH₃); 5.89 (s, 1H, acyclic NH); 6.98-7.45 (m, 7H, Ar-H); 7.98 (s, 1H, cyclic NH).

N-(1*H*-Benzimidazol-2-yl)-6-ethoxy-1,3-benzothiazol-2-amine (3D) – Yield 68%. Anal. Calcd for C₁₆H₁₄ON₄S: C - 61.92%, N - 18.05%, H - 4.55%, Found C - 61.98, N - 18.07%, H - 4.59%; IR (KBr) 3085, 1599, 1456, 1150, 1038, 830, 728 and 672 (benzothiazole with aromatic ring), 3345 (N-H), 1628 (C=N), 1363 (C-S), 1261 (C-O-C), 2905 (CH), ¹H NMR (300 MHz, DMSO-*d*₆): 1.39 (t, 3H, OCH₂CH₃); 3.98 (q, 2H, Ar-OCH₂), 5.80 (s, 1H, acyclic NH); 7.09-7.68 (m, 7H, Ar-H); 8.12 (s, 1H, cyclic NH).

N-(1*H*-Benzimidazol-2-yl)-6-methyl-1,3-benzothiazol-2-amine (3E) – Yield 50%. Anal. Calcd for C₁₅H₁₂N₄S: C - 64.26%, N - 19.98%, H - 4.31%, Found C - 64.24, N - 20.05%, H - 4.36%; IR (KBr) 3085, 1600, 1460, 1155, 1080, 835, 731 and 687 (benzothiazole with aromatic ring), 3364 (N-H), 2908 (CH), 1639 (C=N), 1308 (C-S), ¹H NMR (300 MHz, DMSO-*d*₆): 2.48 (s, 3H, CH₃); 5.79 (s, 1H, acyclic NH); 6.97-7.36 (m, 7H, Ar-H);

Table 2. The zone of inhibition in mm of the compound as well as standard drugs tested for antibacterial activity

Compound	R	R ¹	<i>E. coli</i>		<i>K. species</i>		<i>M. luteus</i>		<i>S. aureus</i>	
			200 µg/mL	100 µg/mL	200 µg/mL	100 µg/mL	200 µg/mL	100 µg/mL	200 µg/mL	100 µg/mL
2A	H	Br	12	10	09	06	11	09	11	09
2B	H	F	11	10	10	08	10	08	09	07
2C	CH ₃	H	11	09	08	00	00	00	08	07
2D	H	OC ₂ H ₅	12	03	06	00	08	07	10	08
2E	H	CH ₃	10	08	07	00	00	00	06	00
3A	H	Br	18	16	09	08	18	16	16	13
3B	H	F	16	14	11	10	16	14	12	10
3C	CH ₃	H	11	09	08	07	10	06	10	07
3D	H	OC ₂ H ₅	14	11	07	06	09	08	14	12
3E	H	CH ₃	11	09	08	06	09	06	08	00
4A	H	Br	21	19	11	08	21	19	17	15
4B	H	F	18	16	14	10	19	17	13	10
4C	CH ₃	H	13	11	09	07	09	08	11	09
4D	H	OC ₂ H ₅	16	13	08	06	10	08	16	13
4E	H	CH ₃	11	10	09	06	09	08	08	00
DMF	-----			00		00		00		00
Novobiocin 100 µg/mL	-----			18		07		35		15
Kanamycin 100 µg/mL	-----			28		07		25		18
Amikacin 100 µg/mL	-----			22		16		32		18

8.02 (s, 1H, cyclic NH).

Synthesis of Substituted-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine Derivatives (4): To a solution of **2** (4.0 mmole) in DMF (15 mL) was added in solution of ethylene diamine (8.0 mmole) in DMF (15 mL) with stirring at room temp. The reaction mixture was refluxed for 8 hrs. The mixture was poured on crushed ice. The resulting solid was dried and recrystallised from ethanol. Physical and chemical data of synthesized compounds are given in Table 1.

6-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine (4A) – Yield 82%. Anal. Calcd for C₁₀H₉BrN₄S: C - 40.42%, H - 3.05%, N - 18.85%, Found C - 41.35%, H - 3.08%, N - 18.76%; IR (KBr) 3070, 1599, 1471, 1100, 1075, 806, 733 and 659 (benzothiazole with aromatic ring), 3351 (N-H), 1637 (C=N), 1304 (C-S), 603 (C-Br), ¹H NMR (300 MHz, DMSO-*d*₆): 3.58 (s, 4H, 2 × CH₂), 5.68 (s, 1H, acyclic N-H), 7.18-7.61 (m, 3H, Ar-H), 8.14 (s, 1H, cyclic N-H).

6-Fluoro-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine (4B) – Yield 75%. Anal. Calcd for C₁₀H₉FN₄S: C - 50.83%, H - 3.84%, N - 23.71%, Found C - 50.81%, H - 3.80%, N - 23.65%; IR (KBr) 3047, 1570, 1498, 1099, 1051, 820, 737 and 644 (benzothiazole with aromatic ring), 3305 (N-H), 1630 (C=N), 1307 (C-S), 1010 (C-F), ¹H NMR (300 MHz, DMSO-*d*₆): 3.56 (s, 4H, 2 × CH₂), 5.60 (s, 1H, acyclic N-H), 7.16-7.58 (m, 3H, Ar-H), 8.09 (s, 1H, cyclic N-H).

4-Methyl-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine (4C) – Yield 58%. Anal. Calcd for C₁₁H₁₂N₄S: C - 56.87%, H - 5.21%, N - 24.12%, Found C - 57.03 %, H - 5.25%, N - 24.18%; IR (KBr) 3090, 1610, 1454, 1162, 1102, 832, 718 and 655 (benzothiazole with aromatic ring), 3398 (N-H), 1640 (C=N), 1320 (C-S), 2857 (CH), ¹H NMR (300 MHz,

DMSO-*d*₆): 3.58 (s, 4H, 2 × CH₂), 2.52 (s, 3H, Ar-CH₃), 5.70 (s, 1H, acyclic N-H), 6.99-7.42 (m, 3H, Ar-H), 8.18 (s, 1H, cyclic N-H).

6-Ethoxy-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine (4D) – Yield 65%. Anal. Calcd for C₁₂H₁₄ON₄S: C - 54.94%, H - 5.38%, N - 21.36%, Found C - 55.01%, H - 5.47%, N - 21.39%; IR (KBr) 3095, 1489, 1452, 1113, 1057, 820, 723 and 671 (benzothiazole with aromatic ring), 3316 (N-H), 1620 (C=N), 1360 (C-S), 1265 (C-O-C), 2898 (CH), ¹H NMR (300 MHz, DMSO-*d*₆): 1.38 (t, 3H, CH₃), 3.30 (s, 4H, 2 × CH₂), 4.04 (q, 2H, Ar- OCH₂), 6.08 (s, H, acyclic NH), 7.18-7.44 (m, 3H, Ar-H), 7.98 (s, H, cyclic NH).

6-Methyl-N-(4,5-dihydro-1H-imidazol-2-yl)-1,3-benzothiazol-2-amine (4E) – Yield 65%. Anal. Calcd for C₁₁H₁₂N₄S: C - 56.87%, H - 5.21%, N - 24.12%, Found C - 57.03 %, H - 5.28%, N - 24.22%; IR (KBr) 3085, 1605, 1450, 1158, 1100, 832, 715 and 653 (benzothiazole with aromatic ring), 3382 (N-H), 1635 (C=N), 1315 (C-S), 2853 (CH), ¹H NMR (300 MHz, DMSO-*d*₆): 3.53 (s, 4H, 2 × CH₂), 2.51 (s, 3H, Ar-CH₃), 5.68 (s, 1H, acyclic N-H), 6.95-7.35 (m, 3H, Ar-H), 8.10 (s, 1H, cyclic N-H).

Antibacterial Activity. All the synthesized compounds were tested against gram positive bacteria *Staphylococcus aureus* and *Micrococcus luteus* and gram negative bacteria *Escherichia coli*, and *Klebsiella species* using paper disc method.³³ Muller Hinton Agar (Hi-Media Pvt. Ltd. Mumbai, India) was used to culture the test bacteria. The microbial culture were grown at 37 °C for 8 hours and then appropriately diluted with sterile 0.8% saline solution. The concentration of test drugs was kept 100 µg/mL in DMF. Standard drugs Novobiocin, Kanamycin and Amikacin were used for comparison. The antimicrobial activity was evaluated by measuring the zones of growth inhibi-

Table 3. Antifeedant Activity

S. No.	Compounds	Fiducial Limits	Slope \pm	Chi. Sq. (3)	LC ₅₀ /LD ₅₀ At 24 hrs.
1	3A	0.25 - 0.40	1.17 \pm 0.14	7.23 (3)	0.31
2	3B	0.64 - 1.16	1.47 \pm 0.16	3.73 (3)	0.83
3	3C	0.45 - 1.09	0.87 \pm 0.13	1.71 (3)	0.64
4	3D	0.29 - 0.51	1.01 \pm 0.13	5.39 (3)	0.37
5	3E	0.37 - 0.63	1.18 \pm 0.14	2.36 (3)	0.47
6	4A	0.30 - 0.59	0.93 \pm 0.13	2.29 (3)	0.41
7	4B	0.51 - 0.97	1.21 \pm 0.14	2.25 (3)	0.67
8	4C	0.84 - 2.34	1.06 \pm 0.15	0.70 (3)	1.24
9	4D	0.43 - 0.87	1.03 \pm 0.14	0.34 (3)	0.58
10	4E	0.43 - 0.72	1.31 \pm 0.14	0.59 (3)	0.54

Table 4. Acaricidal Activity

S. No.	Compounds	Fiducial Limits	Slope \pm	Chi. Sq. (3)	LC ₅₀ /LD ₅₀ At 24 hrs.
1	3A	0.14 - 0.31	0.96 \pm 0.09	7.52 (3)	0.20
2	3B	0.12 - 0.30	0.80 \pm 0.08	6.91 (3)	0.18
3	3C	0.06 - 0.10	1.24 \pm 0.10	14.27 (3)	0.08
4	3D	0.36 - 1.89	0.64 \pm 0.08	3.57 (3)	0.70
5	3E	0.07 - 0.22	0.76 \pm 0.06	5.63 (3)	0.14
6	4A	0.07 - 0.20	0.64 \pm 0.06	8.43 (3)	0.11
7	4B	0.08 - 0.17	0.81 \pm 0.7	9.10 (3)	0.11
8	4C	0.05 - 0.10	0.87 \pm 0.7	20.01 (3)	0.07
9	4D	0.04 - 0.09	0.70 \pm 0.06	4.61 (3)	0.05
10	4E	0.08 - 0.16	0.98 \pm 0.08	15.28 (3)	0.11

tion around disc of test organism and results are given in Table 2.

Antifeedant Activity. The antifeedant activity of these compounds was also carried out by leaf dip method,^{34,35} using fourth instar larvae of *Spodoptera litura*. The leaf discs of about 25 cm² were prepared and dipped for thirty seconds in various test compounds. The leaf discs were air dried to evaporate the excess acetone and then offered for feeding. The insects were allowed to feed for 24 hrs. After 24 hrs. leaf area uneaten was measured by using leaf area meter. The difference between leaf area provided and the leaf area uneaten is taken as amount of leaf area consumed. The feeding inhibition was calculated and used for calculation of effective concentration (EC₅₀/LD₅₀) using Maximum likelihood programmer MLP 3.01. The results of antifeedant activity are summarized in Table 3.

Acaricidal Activity. The acaricidal activity of these compounds was carried out by leaf dip method.^{34,35} Leaf discs of Mulberry (5 cm² diameter) were dipped in different compounds for 30 seconds. The leaf discs were air dried to remove the excess of acetone and placed over wet cotton in Petri plate. The adult female mites were released on treated leaf discs and mortality data were recorded after 24 hours. Mites released on leaf treated only with acetone and tween 20 emulsifier served as control. The mortality data was used for calculation of LC₅₀/LD₅₀ using Maximum Likelihood Programmer MLP 3.01. The results of acaricidal activity are summarized in Table 4.

Contact Toxicity. The contact toxicity of these compounds was carried out by topical application method^{36,37} against larvae of *Spodoptera litura*, which are harmful for Indian crops. First

Table 5. Contact Toxicity

S. No.	Compounds	Fiducial Limits	Slope \pm	Chi. Sq. (3)	LC ₅₀ /LD ₅₀ At 24 hrs.
1	3A	0.92 - 2.60	11.11 \pm 0.16	0.26 (3)	1.36
2	3B	0.41 - 0.61	1.63 \pm 0.15	1.84 (3)	0.49
3	3C	2.37 - 32.67	0.95 \pm 0.19	0.611 (3)	5.38
4	3D	0.45 - 0.68	1.69 \pm 0.16	1.22 (3)	0.55
5	3E	0.40 - 0.60	1.58 \pm 0.15	0.72 (3)	0.48
6	4A	0.02 - 0.27	225 \pm 0.17	4.13 (3)	0.23
7	4B	2.70 - 51.84	0.96 \pm 0.20	0.54 (3)	6.61
8	4C	0.48 - 0.75	1.61 \pm 0.16	2.94 (3)	0.59
9	4D	0.40 - 0.59	1.66 \pm 0.15	5.66 (3)	0.48
10	4E	0.88 - 1.83	1.48 \pm 0.18	1.41 (3)	1.18

Table 6. Stomach Toxicity

S. No.	Compounds	Fiducial Limits	Slope \pm	Chi. Sq. (3)	LC ₅₀ /LD ₅₀ At 24 hrs.
1	3A	1.69 - 7.75	1.28 \pm 0.21	0.38 (3)	2.89
2	3B	0.44 - 0.67	1.65 \pm 0.16	3.89 (3)	0.53
3	3C	1.88 - 14.44	1.01 \pm 0.18	1.06 (3)	3.70
4	3D	0.58 - 0.97	1.54 \pm 0.16	2.33 (3)	0.72
5	3E	0.44 - 0.67	1.69 \pm 0.16	3.30 (3)	0.53
6	4A	0.35 - 0.56	1.40 \pm 0.14	0.82 (3)	0.44
7	4B	0.44 - 0.73	1.40 \pm 0.15	3.84 (3)	0.55
8	4C	0.54 - 0.90	1.49 \pm 0.16	3.39 (3)	0.68
9	4D	0.57 - 1.05	1.32 \pm 0.15	0.63 (3)	0.74
10	4E	3.69 - 38.46	0.77 \pm 0.19	0.39 (3)	12.64

the given compounds were dissolved in acetone and then each compound was applied on the dorsal surface of the larvae. About 10 μ L of each concentration was applied on each larva. Some of the larvae of insect treated by acetone alone, worked as control. Now the mortality data was recorded after 24 hrs, and the treated mortality was corrected with control mortality. These corrected mortality data was used for calculation of LC₅₀/LD₅₀ using Maximum Likelihood programmer MLP 3.01. The results of Contact Toxicity are summarized in Table 5.

Stomach Toxicity. The stomach toxicity of these compounds was carried out by leaf dip method.^{34,35} In this method we used fourth instar larvae of *Spodoptera litura* of an insect which are responsible for the damage of Indian agricultural crops. Ten larvae were used for each replication and three replications were maintained for each compound. The given compounds were dissolved in acetone. The leaf disc were prepared out of castor leaf and dipped in various test compounds for thirty seconds. The leaf discs were air dried to evaporate the excess acetone. (The leaf discs dipped only in acetone were served as control). The mortality data was recorded after 24 hrs, and the treatment mortality were corrected with control mortality. These mortality data was used for calculation of LC₅₀/LD₅₀ using maximum likelihood program, MLP 3.01. The results of Stomach Toxicity are summarized in Table 6.

Results and Discussion

Dimethyl (substituted-1,3-benzothiazol-2-yl)dithioimido-

carbonates (**2**) have been synthesized by the reaction of substituted-2-aminobenzothiazoles (**1**) with carbon disulphide, sodium hydroxide and methyl iodide in ice cold solution with DMF as solvent. Further *N*-(1*H*-benzimidazol-2-yl)-substituted-1,3-benzothiazol-2-amines (**3**) and substituted-*N*-(4,5-dihydro-1*H*-imidazol-2-yl)-1,3-benzothiazol-2-amines (**4**) were synthesized by the reaction of compound **2** with *o*-phenylene diamine and ethylene diamine respectively. The structures of all the synthesized compounds were established on the basis of spectroscopic and analytical data. The elemental analysis (C, N and H) found for all the condensed products were in close agreement with the calculated values, the infrared (IR) spectrum of compounds **3** and **4** display two characteristic bands at 3350 - 3250 and 2910 - 2860 cm⁻¹ due to N-H and CH₂ vibrations, respectively.

Antibacterial Activity. The antibacterial activity of all the synthesized compounds were tested *in-vitro* against pathogenic *Escherichia coli*, *Klebsiella species*, *Micrococcus luteus* and *Staphylococcus aureus* at 200 µg/mL and 100 µg/mL, and the results were compared with some standard drugs like Novobiocin, Kanamycin and Amikacin. In case of *E. coli* Compounds **3A**, **3B**, **4A** and **4B** exhibited higher activity at 200 µg/mL while the rest of compounds showed moderate activity. In case of *Klebsiella spp.* compounds **3B** and **4B** showed higher activity than the rest of compounds. In case of *Micrococcus luteus* and *S. aureus* compounds **3A**, **4A**, **4B** and **3B** show higher efficacy than rest of compounds. The presence of halogen groups, in **3A**, **3B**, **4A** and **4B** play an important role in activity. Sometimes these compounds when present in low concentrations may cause bacteriostatic conditions which slow down the growth of bacteria (Table 2).

Antifeedant Activity. The Antifeedant activity of the newly synthesized compounds was tested by leaf dip method^{34,35} against larvae of *Spodoptera litura*. The results clearly indicate that the compounds show higher, moderate and less antifeedant activity against the larvae of the insect. Compounds **3A**, **3D**, **3E** and **4A** showed higher activity, compounds **3C**, **4B** and **4D** showed moderate activity. It may be found that these compounds may cause a spasm condition in insects by interacting with the active site of the enzyme responsible for nervous breakdown in insects (Table 3).

Acaricidal Activity. The Acaricidal activity of these compounds was performed by the same method, as in the case of Antifeedant activity, against *Tetranychus urticae*, a species of mite using acetone as a standard. The results obtained clearly show that compound **3C**, **3E**, **4C** and **4D** showed the highest acaricidal activity with respect to other compounds. It is reported that the compounds which are easily soluble in polar solvent have higher activity against microbes and insect, pests or mites.⁴¹ Rest compounds showed moderate acaricidal activity against the mites (Table 4).

Contact Toxicity. The contact toxicity of these compounds was carried out by topical application method^{36,37} against larvae of *Spodoptera litura*. The results clearly indicate that the compounds show moderate and lower contact toxicity against the larvae of the insect. Compounds **3B**, **3D**, **3E**, **4A**, **4D** and **4C** showed moderate activity and the rest of the compounds showed lower to moderate activity against the mites (Table 5).

Stomach Toxicity. The stomach toxicity of these compounds was carried out by leaf dip method.^{34,35} In this method we used fourth instar larvae of *Spodoptera litura*. The results clearly indicate that the compounds show moderate and lower stomach toxicity against the larvae of the insect. Compounds **3B**, **3E**, **4A** and **4B** showed moderate activity and the rest of the compounds showed lower to moderate activity against the mites (Table 6).

Conclusions

All the newly synthesized compounds were screened for antibacterial activity at a concentration of 200 µg/mL and 100 µg/mL using DMF as a control. Novobiocin, Kanamycin and Amikacin were used as standard against gram positive and gram negative bacteria. The data in the Table 2 indicates that among the synthesized compounds **3A**, **3B**, **4A** and **4B** possess a broad spectrum activity. However, the activities of the tested compounds are much less than those of standard antibacterial agents used. Antifeedant activity, contact toxicity and stomach toxicity against *Spodoptera litura* and acaricidal activity against *Tetranychus urticae* were moderate for test compounds. From the results, it is clear that these compounds would be of better use in drug development to combat bacterial infections and as pesticides in future.

Acknowledgments. The authors are thankful to Head, Department of Chemistry, Govt. College, Ajmer for providing necessary laboratory facilities. We are also grateful to Dr. Ashish Bhatnagar, Head, Department of Microbiology, M. D. S. University, Ajmer for facilities provided to carry out antibacterial studies.

References

1. Besson, T.; Benetau, V.; Guillard, J.; Leonce, S.; Pfeiffer, B. *J. Med. Chem.* **1999**, *34*, 1053.
2. Caleta, I.; Gridisa, M.; Mrovs, S. D.; Cetina, M.; Tralic, K. V.; Pavelic, K. *Il Farmaco*. **2004**, *59*, 297.
3. Suvarna, K.; Swain, S. P.; Gandhi, A. M. *Indian J. Pharm. Sci.* **2007**, *69*(1), 46.
4. Shastri, C. S.; Joshi, S. D.; Aravind, M. B.; Veerapur, V. P. *Ind. J. Het. Chem.* **2003**, *13*, 57.
5. Yilidiz-Oren, I.; Yalcin, I.; Aki-Sener, E.; Ucar, Turk, N. *Eur. J. Med. Chem.* **2004**, *39*, 291.
6. Latrofa, A.; Franco, M.; Lopodota, A.; Rosato, A.; Carone, D.; Vitali, C. *Il Farmaco*. **2005**, *60*, 291.
7. Kaur, H.; Kumar, S.; Singh, I.; Saxena, K. K.; Kumar, A. *Digest J. Nanomaterials and Biostructures* **2010**, *5*(1), 67.
8. Oketani, K.; Nagakura, N.; Harada, K. T. *Eur. J. Pharmacol.* **2001**, *422*, 209.
9. Paramashivappa, R.; Phani, K. P.; Rao, P. V. S.; Rao, S. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 657.
10. Nagarajan, S. R.; De, C. G. A.; Getman, D. P.; Lu, H. F.; Sikorski, J. A.; Walker, J. L. *Bioorg. Med. Chem. Lett.* **2003**, *11*, 4769.
11. Florence, D.; Antonio, A.; Carole, D. G.; Maxime, R.; Erik, D. C.; Pierre, T. *Eur. J. Med. Chem.* **2004**, *39*, 685.
12. Yang, B. Q.; Yang, P. H.; Zhu, A. L. *Chinese Chemical letters* **2003**, *14*(9), 901.
13. Saggu, J. S.; Sharma, R.; Dureja, H.; Kumar, V. *J. Indian Inst. Sci.* **2002**, *82*, 177.
14. Ayhan, K. G.; Kus, C.; Coban, T.; Can, Eke, B. *J. Enzyme Inhib.*

- Med. Chem.* **2004**, 19(2), 129.
15. Tewari, A. K.; Mishra, A. *Indian J. Chem.* **2006**, 45(B), 489.
16. Mahajan, S. S.; Nandre, R. G. *Indian J. Chem.* **2006**, 45(B), 1759.
17. Le, H. T.; Lemaire, I. B.; Gilbert, A. K.; Jolicoeur, F.; Yang, L.; Leduc, N. *JPET* **2004**, 309, 146.
18. Rao, A.; Chimirri, A.; Ferro, S.; Monforte, A. M.; Monforte, P.; Zappalà, M. *ARKIVOC* **2004**, 147.
19. Navarrete, V. G.; Cedillo, R.; Hernandez, C. A.; Yopez, L.; Valdez, J.; Morales, R.; Coryes, R.; Catillo, R. *Bioorg. Med. Chem. Letter* **2001**, 11(2), 187.
20. Evers, D. L.; Gloria, K.; Ptak, R. G.; Emmer, B. T.; Shin, D.; Drach, J. C. *Antimicrobial agents & chemotherapy* **2004**, 48(10), 3918.
21. Kilcigil, G. A.; Altanlar, N. *Turk. J. Chem.* **2006**, 30, 223.
22. Nawrocka, W. *Boll Chim. Farm.* **1996**, 135(1), 18.
23. Rivara, M.; Zuliani, V.; Cocconcelli, G.; Morini, G. V.; Comini, M.; Rivara, S. *Bioorg. Med. Chem. Lett.* **2006**, 14(5), 1413.
24. Shaya, Y. A. R.; Ahmed, M. S.; Elsharief, Saied, M. E. K.; Abdulkhaliq, M. A. A. *Heteroatom Chem.* **2006**, 17(7), 634 & *Chem-Inform.* **2007**, 38, 12.
25. Pandey, J.; Tiwari, V. K.; Verma, S. S.; Chaturvedi, V.; Bhatnagar, S.; Sinha, S.; Gaikwad, A. N.; Tripathi, R. P. *Eur. J. Med. Chem.* **2009**, 44, 3350.
26. Dahiya, R.; Kumar, A. *E. J. Chem.* **2008**, 5, 1133.
27. Banfi, E.; Scialino, G.; Zampieri, D.; Mamolo, M. G.; Vio, L.; Ferrone, M.; Fermeglia, M.; Paneni, M. S.; Priel, S. *J. Antimicrob. Chemother.* **2006**, 58, 76.
27. Ulusoy, N.; Gursu, E.; Ozkirimil, S.; Ekinici, A. C.; Dikici, I. *Indian J. Chem.* **2003**, 42(B), 2853.
28. Sharma, D.; Narasimhan, B.; Kumar, P.; Judge, V.; Narang, R.; Clercq, E. D.; Balzarini, J. *Eur. J. Med. Chem.* **2009**, 44(6), 2347.
29. Atia, A. J. K. *Molecules* **2009**, 14, 2431.
30. Ojha, K. G.; Jain, S. K.; Gupta, R. R. *Synth. Commun.* **1979**, 9(6), 457.
31. Gupta, R. R.; Ojha, K. G.; Kumar, M. *J. Heterocycl. Chem.* **1980**, 17, 1325.
32. Cruickshank, R.; Duguid, J. P.; Marmion, B. P.; Swam, H. A. *The Practice of Medical Microbiology*, 12th Ed.; Churchill Livingstone: London, 1975; p 544.
33. Shelton, A. M.; Robertson, J. L.; Tang, J. D. *J. Econ., Entomol.* **1993**, 86(9), 697.
34. Jinfeng, H.; Pei, L.; Xueyan, S.; Xiwu, G. *J. Insect. Sci.* **2008**, 8(3), 9.
35. Leonardi, M. G.; Cappelloza, S.; Ianne, P.; Cappelloza, L.; Parenti, P.; Giordana, B. *Compendium of Biochemistry and Physiology* **1996**, 113(B), 361.
36. Ludvik, G. F. *J. Econ. Entomol.* **1953**, 46, 364.
-